<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405688</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-PRO-TRANSFU-DREPANO 2</org_study_id>
    <nct_id>NCT03405688</nct_id>
  </id_info>
  <brief_title>Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors</brief_title>
  <official_title>Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanane EL KENZ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium.
      As blood donors are not tested for this allele, their heterozygous status is unknown.
      However, guidelines recommend to transfuse sickle cell patients with blood that is negative
      for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to
      evaluate the impact of transfusion with blood originating from heterozygous donors on the
      transfusion performance and the improvement of clinical status of the sickle cell disease
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level -patient</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Hemoglobin level (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level -patient</measure>
    <time_frame>1 hour after blood transfusion</time_frame>
    <description>Hemoglobin level (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of 'S' type hemoglobin -patient</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>% of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of 'S' type hemoglobin -patient</measure>
    <time_frame>1 hour after blood transfusion</time_frame>
    <description>% of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level - transfused blood</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Hemoglobin level (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of 'S' type hemoglobin -transfused blood</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>% of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transfusion yield</measure>
    <time_frame>1 hour after blood transfusion</time_frame>
    <description>Computed by means of a formula taking the level of hemoglobin, the % of 'S' type hemoglobin and the body surface into account.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical complications</measure>
    <time_frame>1 month</time_frame>
    <description>List of medical complications having occured after a surgery. Applicable only to the 'transfusion prior to surgery' groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>1 month</time_frame>
    <description>Length of stay within the hospital. Applicable only to the 'acute transfusion' groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay post transfusion</measure>
    <time_frame>1 month</time_frame>
    <description>Length of stay within the hospital after a blood transfusion. Applicable only to the 'acute transfusion' groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of blood transfusions</measure>
    <time_frame>1 month</time_frame>
    <description>Number of blood transfusions. Applicable only to the 'acute transfusion' groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital re-admission</measure>
    <time_frame>1 month</time_frame>
    <description>Hospital re-admission. Applicable only to the 'acute transfusion' groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>1 month.</time_frame>
    <description>Mortality rate. Applicable only to the 'acute transfusion' groups</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Sickle Cell Trait</condition>
  <arm_group>
    <arm_group_label>Acute transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Acute transfusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood donor not bearer of the sickle cell disease allele (HbAA genotype)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Chronic transfusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood donor not bearer of the sickle cell disease allele (HbAA genotype)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transfusion prior to surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Transfusion prior to surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood donor not bearer of the sickle cell disease allele (HbAA genotype)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Extra blood samples taken for laboratory analysis</description>
    <arm_group_label>Acute transfusion</arm_group_label>
    <arm_group_label>Control - Acute transfusion</arm_group_label>
    <arm_group_label>Chronic transfusion</arm_group_label>
    <arm_group_label>Control - Chronic transfusion</arm_group_label>
    <arm_group_label>Transfusion prior to surgery</arm_group_label>
    <arm_group_label>Control - Transfusion prior to surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients with sickle cell disease within the CHU Brugmann and the Queen Fabiola
        Children's Hospital (HUDERF)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <phone>3224772409</phone>
    <email>marie.deleers@chu-brugmann.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanane El Kenz, Ph Biol</last_name>
    <phone>3224772734</phone>
    <email>hanane.elkenz@chu-brugmann.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Hanane EL KENZ</investigator_full_name>
    <investigator_title>Head of Blood Bank</investigator_title>
  </responsible_party>
  <keyword>Sickle cell</keyword>
  <keyword>Heterozygous</keyword>
  <keyword>Blood donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Sickle Cell Trait</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

